Nucynta (Tapentadol HCl) Patent Expiration, LOE Window & CMS Spending

Nucynta (Tapentadol HCl) by Collegium: FDA Orange Book LOE 2027-01-03, 2 AB generics, $68.0M 2024 CMS Part D & Medicaid spend, and 32 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorCollegium
FDA Application & PathwayN022304 (NDA)
Exclusivity / Cliff HorizonImmediate Cliff (2025-2027)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2027-01-03
Orange Book Patents (*PED Extensions)0 patents (1 *PED)
Active AB-Rated Generic Competitors2
2024 CMS Total Public Spend$68.0M
2024 Medicare Part D Spend$56.1M
2024 Medicaid Spend$11.9M
Reported Wholesale Price Change (CA SB 17)32 WAC filings (max 38.9% 2-yr change)